STEP I: Patients must not have active, uncontrolled infection Patient must not have an active uncontrolled infection Any active acute or chronic or uncontrolled infection Patients with active, uncontrolled infection Unstable systemic disease or active uncontrolled infection Active uncontrolled infection; Active infection requiring systemic treatment or any uncontrolled infection CTCAE grade 2 uncontrolled with antibiotics Active, uncontrolled infection Active clinically serious and uncontrolled infection Active uncontrolled infection Active uncontrolled infection Uncontrolled active infection Uncontrolled active infection Active or uncontrolled infection Have an active, uncontrolled infection Any uncontrolled active systemic infection Active uncontrolled infection. Uncontrolled active infection Active and uncontrolled infection at time of transplantation Active uncontrolled infection Active uncontrolled infection Active uncontrolled infection Active uncontrolled infection Uncontrolled active infection; Patients with an active or uncontrolled infection. Active pneumonitis or uncontrolled infection Patient must not have an active, uncontrolled infection Patients with documented active, uncontrolled infection at the time of study entry Patients who have an active or uncontrolled infection are excluded Active uncontrolled infection Subject has active, uncontrolled infection Active uncontrolled infection Subject has an active uncontrolled infection. Patients must not have active, uncontrolled infection Subject has active, uncontrolled infection Have evidence of uncontrolled, active infection <7 days prior to administration of study medication. Active or uncontrolled infection Uncontrolled active infection Uncontrolled active infection Patients with active or uncontrolled systemic infection. Free of active uncontrolled infection at the time of study entry Active, uncontrolled infection Active uncontrolled infection Any uncontrolled active systemic infection. Uncontrolled active infection within one week prior to first dose Uncontrolled medical disease(s) or active, uncontrolled infection Active uncontrolled serious infection or sepsis at study enrollment Subject has an active uncontrolled infection. Active uncontrolled serious infection or sepsis at study enrollment Uncontrolled active infection Active uncontrolled infection No active uncontrolled infection Active, uncontrolled systemic infection Patients who have uncontrolled active infection Active uncontrolled infection Active uncontrolled infection Uncontrolled active infection or illness Patients with an active or uncontrolled infection. Subjects with an active uncontrolled infection. Active major systemic or local uncontrolled infection Known active uncontrolled systemic infection Uncontrolled active infection Have a significant uncontrolled infection active infection Have significant, uncontrolled active infection Uncontrolled active infection Patients with active, uncontrolled infection Serious uncontrolled active infection Active uncontrolled infection Has an active, uncontrolled infection; Active or uncontrolled infection Active uncontrolled infection at time of enrollment or documented fungal infection within 3 months Patients with active or uncontrolled systemic infection. Active, uncontrolled infection Active uncontrolled infection Subject has an active uncontrolled infection Active uncontrolled infection; Active uncontrolled opportunistic infection Any active or uncontrolled infection Active, uncontrolled infection Active or uncontrolled infection Active and uncontrolled infection at the time of transplantation Any uncontrolled active systemic infection Patient is known to have an uncontrolled active systemic infection Active, uncontrolled infection Active uncontrolled infection Active/uncontrolled infection Active, uncontrolled infection Active, uncontrolled infection Active and uncontrolled infection Evidence of uncontrolled active infection Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection Any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures. Any uncontrolled active systemic infection Active infection that requires systemic treatment Subject has an active infection Patients with a clinically apparent active infection will not be eligible (please note, an isolated elevation in the white blood cell count, by itself, does not constitute evidence of an infection) Active infection Has an active systemic infection Active infection Active serious infection Active infection not adequately responding to appropriate therapy Active infection Evidence of active infection Patients with active infection Recent (< 4 weeks) active, documented, cervical infection Patients with active infection Active infection of any kind. DONOR: Evidence of active infection No active or uncontrollable infection. Active infection Active infection or corneal ulcer (e.g. keratitis) Active or incompletely treated local infection at the planned treatment site(s) and/or systemic infection Active uncontrolled infection or severe systemic infection (enrollment is possible after control of infection). Active infection, including any active viral infection, =< 5 days prior to registration DONOR: Active infection Patients with active systemic, pulmonary, or pericardial infection Active infection Active infection or corneal ulcer DONOR: Active infection Active infection Ongoing or active systemic infection or active hepatitis B or C virus infection No active or uncontrollable infection HIV infection, active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or that can cause a severe disease and pose a severe danger to lab personnel working on patients' blood or tissue. If positive test results are not indicative of an active infection, patients can be included. Active infection Active infection not adequately responding to appropriate therapy Active infection =< 5 days prior to registration Active systemic, pulmonary, or pericardial infection Patients with active infection Active infection DONOR: Evidence of active infection Active infection not responding to appropriate therapy as determined by study chair Active infection that is not responding to antimicrobial therapy TREATMENT: Patients with severe active infection No evidence of active infection and no serious infection within the past month Evidence of active infection, or serious infection within the past month No evidence of active infection and no serious infection within the past month Evidence of active infection, or serious infection within the past month Active herpes zoster infection Active infection =< 5 days prior to registration Patients with active infection No active infection Evidence of active infection or serious infection within the past month RECIPIENT: Active infection refractory to antimicrobial therapy Active systemic infection No evidence of active infection and no serious infection within the past month Evidence of active infection, or serious infection within the past month Active infection Active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold, or human immunodeficiency virus (HIV) infection Active systemic, pulmonary, or pericardial infection Active infection that is not responding to antimicrobial therapy Active infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days) Active infection at time of transplantation (including active infection with aspergillus or other mold within 30 days) Current active serious infection Patients with active systemic, pulmonary, or pericardial infection Serious active infection Active infection. Patients with an active infection Subjects with bacteremia with documented microbiological evidence of another source of infection (eg, osteomyelitis, pneumonia, skin infection, urinary tract infection, joint infection, or abdominal infection) known to be due to the same organism cultured from the blood; Active infection, chronic or severe infection requiring ongoing antimicrobial therapy. Evidence of active infection, or serious infection within the past month Active infection Active infection =< 5 days prior to registration Active infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days) Active infection Active infection not adequately responding to appropriate therapy. Patients with active infection are ineligible Active infection =< 5 days prior to registration Active serious infection Patient may have no active uncontrollable systemic infection Active ear/sinus infection Patients with active infection Subjects with an active infection Active infection that is not responding to antimicrobial therapy They have active diarhhea. Active infection Active infection Active, unresolved infection Active infection or corneal ulcer (e.g., keratitis) Evidence of active infection within 2 weeks prior to first dose of study treatment. Patients are ineligible if they have an active infection Active infection; Active infection not adequately responding to appropriate therapy. Active infection (any infection requiring treatment). Infection Patients with an active infection. No active systemic, pulmonary, or pericardial infection Current systemic infection or suspicion of active bacterial infection Active infection Active and uncontrolled infection; patients with an active infection receiving treatment and hemodynamically stable for 48 hours may be entered into the study Patient has evidence of active systemic, pulmonary, or pericardial infection. Evidence of active infection or serious infection (e.g., septic shock with multi-organ dysfunction) within the past month Active unresolved infection Active infection (any infection requiring treatment). Active, unresolved infection No evidence of active infection and no serious infection within the past month Evidence of active infection, or serious infection within the past month No evidence of active infection and no serious infection within the past month Evidence of active infection, or serious infection within the past month Active herpes simplex or herpes zoster. Subjects on prophylaxis for herpes who started taking medication at least 30 days prior to study entry, and have no active signs of active infection, and whose last active infection was more than 6 months ago, may enter the study, and should continue to take the prescribed medication for the duration of the study. Current evidence of invasive fungal infection (blood or tissue culture); patients with recent fungal infection must have a subsequent negative cultures to be eligible; known HIV (new testing not required) or evidence of active hepatitis B or C infection (with rising transaminase values) Active serious infection Active infection Known active infection, or major episode of infection within 4 week prior to the start of Cycle 1 Serious active infection or gastrointestinal disease Active infection\r\n* Active infection includes patients with positive blood cultures No active infection Active systemic infection Active infection that is not responding to antimicrobial therapy Active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold, or human immunodeficiency virus (HIV) infection Active infection Active systemic infection Any evidence of serious active infection. Known active systemic infection (Grade ?2). No evidence of active infection and no serious infection within the past month Evidence of active infection, or serious infection within the past month Active, clinically serious infection greater than CTCAE grade 2. Patients may be eligible upon resolution of the infection. Acute, active infection within 14 days of enrollment Patients with active lung infection or active pulmonary edema Active serious infection (pulmonary infiltrates or lesions are allowed only after the appropriate diagnostic testing is negative for infection or appropriate therapy was initiated for probable infection) Concurrent, acute, active infection, or treatment for infection, other than oral thrush or genital herpes, within 14 days of enrollment Active infection No active infection Infection:\r\n* Local infection at the puncture site\r\n* Systemic infection, osteomyelitis, discitis Active infection Concurrent active infection Patients with active infection at time of biopsy No active infection Active infection. Known active infection. Infection Active infection Patients should not have any clinical evidence of an active infection at the time of enrollment Patients with active pulmonary or pericardial infection Known active infection Evidence of active infection Infection Infection A serious active infection (> grade 2) within 7 days of enrollment Currently active infection Active systemic, pulmonary, or pericardial infection Documented or suspected infection Active infection that is not responding to antimicrobial therapy Active infection Serious active infection at the time of pre-study screening. Active infection Active infection with hepatitis A, B, or C; active infection is defined as serologic positivity and elevated liver function tests Active infection Active lung infection EXCLUSION - STUDY 1: Active infection Active Infection Active cutaneous infection or inflammation Local or systemic infection Patients must not have an active infection Active systemic infection Active infection at time of transplantation (including active infection with aspergillus or other mold within 30 days) Active infection. Active systemic infection or skin infection at or near the acupuncture sites Clinically active infection; an active infection may alter the biodistribution of 18F-FLT Evidence of active infection within 14 days of study enrollment No active skin infection Recognized concurrent active infection Active infection Active infection Patients with active systemic, pulmonary, or pericardial infection Patients that have recognized concurrent active infection Active infection Active infection Active infection (any infection requiring treatment). Patients with untreated or active hepatitis B or C infection Are untreated. Untreated active HBV Symptomatic untreated strictures Previously untreated Presence of active untreated infection Untreated active infection Untreated active infection Uncontrolled active, untreated, or progressive infection Untreated active major depression Uncontrolled active, untreated, or progressive infection Untreated active infection Untreated active infection Presence of any untreated systemic infection Patients with untreated or uncontrolled neuropsychiatric illness Evidence of untreated infection Presence of active untreated infection Patient has untreated severe hypothyroidism Patients must be untreated with radiation above the clavicles Active untreated infection Patients with known untreated hepatitis C Chronic active untreated hepatitis B or C infection Untreated systemic infection Untreated or uncontrolled 2nd malignancy Hepatitis B or C infection (HBV), or untreated systemic infection Untreated hepatitis B infection The presence of co-existing medical conditions that would limit compliance with study medications, including, but not limited to active infection, active or untreated cardiac or pulmonary disease, or malignancy Patients must be previously untreated UNTREATED PRIMARY: Active untreated infection Active untreated infection Has untreated hypo- or hyperthyroidism; Untreated bladder infection Patients with untreated clinically relevant hypothyroidism Patients with any of the following conditions: untreated gastrointestinal reflux disease; untreated diabetes mellitus; active thrush; active oral infection; active mucositis Patients with any of the following conditions: untreated gastrointestinal reflux disease; untreated diabetes mellitus; active thrush; active oral infection; active mucositis Untreated active infection Untreated; OR Patients with uncontrolled infection Patients with uncontrolled infection Uncontrolled infection Serious, uncontrolled infection Research participants with uncontrolled infection Evidence of severe of uncontrolled infection. Patients with uncontrolled infection are excluded Uncontrolled hydropericardium Uncontrolled bacterial infection Uncontrolled infection Any uncontrolled infection Patients must be free of uncontrolled infection Patients who have an uncontrolled infection Uncontrolled infection Uncontrolled hepatitis B or C infection Uncontrolled infection Serious (i.e., >= grade 3) uncontrolled infection No uncontrolled infection Serious (ie, >= grade 3) uncontrolled infection Uncontrolled infection Uncontrolled infection Uncontrolled infection Patients who have an uncontrolled infection Patients with uncontrolled infection Uncontrolled infection Serious, uncontrolled, concurrent infection(s) Uncontrolled infection Uncontrolled infection Patients with an uncontrolled serious infection Uncontrolled infection Uncontrolled infection Patients with uncontrolled infection Uncontrolled infection Absence of uncontrolled infection Uncontrolled infection Patients must not have uncontrolled infection Uncontrolled or current infection Subjects who have an uncontrolled infection Patients with serious, uncontrolled, concurrent infection(s) Patients with uncontrolled infection are excluded Uncontrolled infection Uncontrolled infection Uncontrolled infection Patients with uncontrolled infection Uncontrolled infection Have uncontrolled hepatitis B or C infection Uncontrolled infection Evidence of an ongoing, uncontrolled systemic infection or an uncontrolled local infection requiring therapy at the time of start of study therapy Uncontrolled infection Uncontrolled infection Uncontrolled infection Patients with uncontrolled infection or systemic disease Serious, uncontrolled, concurrent infection(s) Uncontrolled or serious infection Uncontrolled infection Evidence of ongoing, uncontrolled systemic infection or an uncontrolled local infection requiring therapy at the start of study. Uncontrolled infection or systemic disease. Uncontrolled infection Serious, uncontrolled, concurrent infection(s) No serious, uncontrolled, concurrent infection(s) Uncontrolled infection; Have an uncontrolled infection An uncontrolled infection Uncontrolled infection at initiation of protocol treatment Patients with uncontrolled infection at the time of study entry Serious, uncontrolled, concurrent infection(s) Uncontrolled infection Has an uncontrolled infection on the day of randomization Uncontrolled infection Patient must not have an uncontrolled infection Active hepatitis B or hepatitis C infection Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection Known history of hepatitis C infection or suspected currently active hepatitis C infection; known or suspected history of hepatitis B infection will be excluded when any of the following conditions are met:\r\n* Received hematopoietic stem cell transplantation (either allogenic or autologous), or\r\n* Received any rituximab-containing treatment regimen in the last 12 months before entering the study, or\r\n* Active hepatitis B as deemed by serology or viral load Active hepatitis B infection Active hepatitis C infection Active hepatitis A, B, or C infection. Has a known history of hepatitis B and/or hepatitis C infection Active or chronic hepatitis B or C infection\r\n* Previously infected with evidence of immunity and no evidence of active hepatitis is not an exclusion criterion Active hepatitis B and/or hepatitis C infection Active Hepatitis B or C infection Active hepatitis A, B, or C infection A history of active hepatitis B and/or hepatitis C infection Participant has known infection with hepatitis B or hepatitis C. ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Patients with known active hepatitis B and/or active hepatitis C infection Patients with known active Hepatitis B or Hepatitis C infection Active hepatitis A, hepatitis B, or hepatitis C infection Patients with active hepatitis A, hepatitis B, or hepatitis C infection Active hepatitis B or C infection Active hepatitis B or C infection Patients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids Known hepatitis B or hepatitis C infection Subjects with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids. Active hepatitis B or C infection COHORT 3: ENDOMETRIAL CANCER: Patients who have known active hepatitis B, or hepatitis C infection Active Hepatitis C infection. Subjects who have been treated for Hepatitis C infection can be included if they have documented sustained virologic response of ? 12 weeks. Known active hepatitis infection Active hepatitis A, hepatitis B, or hepatitis C infection Active hepatitis B or hepatitis C infection Has an active bacterial, fungal, and/or known viral infection; patients with known human immunodeficiency virus (HIV) infection are excluded given the potential for interactions between antiretroviral agents and abemaciclib, and the potential for increased risk of life threatening infection with therapy that is myelosuppressive; patients with known hepatitis B or hepatitis C infection are excluded only if there is evidence of active infection (detectable hepatitis B surface antigen, detectable hepatitis C ribonucleic acid [RNA]) Active hepatitis B or C infection Active hepatitis A, B or C infection Active infection with hepatitis B; active or chronic infection with hepatitis C Prior or ongoing liver disease including known cirrhosis, active hepatitis B or C infection; not to exclude patients with a distant history of resolved hepatitis A infection Known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids Known human immunodeficiency virus or hepatitis C infection only if the patient is taking medications that are excluded per protocol, active hepatitis B, or active hepatitis C infection. Active hepatitis B or C infection Active hepatitis B or C infection Known history of hepatitis C or known active hepatitis B infection No active infection with Hepatitis B. No active infection with Hepatitis C. Known hepatitis B or C infection Patients with active hepatitis A, hepatitis B, or hepatitis C infection Active, uncontrolled infection including known hepatitis B or C Known or suspected active hepatitis B or C infection Known active hepatitis B or C infection, or HIV infection. Active hepatitis B or hepatitis C infection Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation Active hepatitis B or hepatitis C infection Participants with active hepatitis A, B or C infection. Known active hepatitis B and/or hepatitis C infection Patients tested positive for hepatitis B or with a known, active hepatitis C infection Known active Hepatitis B or C infection Negative for hepatitis A, B, or C infection Patients with active hepatitis B and/or hepatitis C infection Active hepatitis B or hepatitis C infection Known active hepatitis B or C infection Any history of hepatitis B infection Relapsed/refractory MCL: Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation Newly diagnosed MCL: Known HIV infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation Patients with active hepatitis B and/or hepatitis C infection Active hepatitis B or C infection Known positivity for hepatitis B infection Known active hepatitis C infection Patients with a history of hepatitis B with persistent infection. Active, uncontrolled infection (e.g. Hepatitis A, B, or C) Active infection requiring systemic therapy, known infection of HIV, Hepatitis B, or Hepatitis C. Subject has known active hepatitis B or hepatitis C infection. Active hepatitis B or hepatitis C infection at the time of screening Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids. Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids Known HIV infection or active infection with hepatitis B or C. Patients with unknown status at the time of enrollment must be tested during screening. Serologic status reflecting active hepatitis B or C infection. Active viral hepatitis infection. Subjects with history of hepatitis infection that is not active are eligible. Active hepatitis B or hepatitis C infection Active hepatitis B or C infection Known human immunodeficiency virus (HIV) infection. Patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody). Known hepatitis C infection is allowed as long as there is no active disease. These patients should be optimized by GI consultation for hepatitis B and infectious disease consult for hepatitis C. Known human immunodeficiency virus (HIV) infection. Patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody). Known hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation. Has known active hepatitis B or hepatitis C infection Known active hepatitis B or active hepatitis C infection; participants who have prior hepatitis C infection but who have received an antiviral treatment and show no detectable viral ribonucleic acid (RNA) for 6 months after completion of treatment are eligible Known active hepatitis B or C infection or HIV infection. Active hepatitis B or C infection Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection Known, active hepatitis A, B, or C infection Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection Co-infection with hepatitis B Known active hepatitis A, B, or C infection that requires treatment Active infection with hepatitis B; active or chronic infection with hepatitis C Active hepatitis B or C infection Patients with active hepatitis B or active hepatitis C infection Active hepatitis B or C infection Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening Active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive ) Active tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active hepatitis B, hepatitis C or HIV infection Active hepatitis B or C infection based on screening blood testing Hepatitis D infection in subjects with hepatitis B Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening Active tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active hepatitis B, hepatitis C or HIV infection. Has known active Hepatitis B or Hepatitis C infection. Recent (< 1 week ago) clinically significant infection, active tuberculosis or evidence of active hepatitis B, hepatitis C or HIV infection No active infection with hepatitis B Known active hepatitis B or hepatitis C infection. Active infection or past hepatitis B or C infection Hepatitis B or C infection Known history of active hepatitis B or hepatitis C infection Active hepatitis B or hepatitis C infection Hepatitis B or C infection known or suspected past hepatitis B infection, Active hepatitis B infection, active hepatitis C infection or known HIV carrier. Has active hepatitis B or hepatitis C infection, or co-infection with both hepatitis B and C virus Active hepatitis B or C infection History of human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation; HIV screening is not required for this study Active, uncontrolled infection, including hepatitis B, hepatitis C Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation Evidence of active hepatitis B (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody) or active hepatitis C infection; evidence of active human immunodeficiency virus (HIV) infection Known active hepatitis B or C infection No active hepatitis B or C infection Patients with active hepatitis A, hepatitis B, or hepatitis C infection Active hepatitis B infection, active hepatitis C infection Patients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids. Active hepatitis B or C infection. Active hepatitis B or C infection Participant has known active infection with hepatitis B or hepatitis C virus; hepatitis B and C serology testing is not required, unless active infection is suspected Known active hepatitis B or C infection Active hepatitis A, B, or C infection Active hepatitis B or hepatitis C infection Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation Active hepatitis B or C infection Subjects with known active hepatitis (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids Active hepatitis B or C infection Active hepatitis B or C infection Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection Patients known to be positive for hepatitis B or to have active hepatitis C infection; Evidence of active or prior hepatitis infection. Known infection with HIV and active infection with hepatitis B or C. Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation 7. Subjects with known infection with hepatitis A, B or C (testing not required). Known infection with HIV or active infection with hepatitis B or hepatitis C Active hepatitis B or C infection History of HIV infection or acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines Known HIV infection and/or active Hepatitis B or C infection Uncontrolled, active infection; patients who are known to have HIV infection/ seropositivity, Hepatitis A, B, or C, or CMV reactivation Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection Active hepatitis B infection active hepatitis C infection and/or known HIV carrier. Uncontrolled, active infection; patients who are known to have HIV infection/ seropositivity, Hepatitis A, B, or C, or CMV reactivation Evidence of hepatitis B infection DONOR: Evidence of hepatitis B infection Known active hepatitis B or C infection Active hepatitis B or C infection Active hepatitis B or C infection Patients with documented active hepatitis B or C infection Active hepatitis B or active hepatitis C infection Hepatitis B or hepatitis C active infection Known active infections Patients with clinically significant active infections No active serious infections or other conditions precluding chemotherapy Active serious infections not controlled by antibiotics Must have no ongoing active, uncontrolled infections (afebrile for > 48 hours off antibiotics) Any evidence of serious active infections; any infections being treated must complete antibiotic therapy at least 7 days before planned first dose. Patient with active, uncontrolled infections (patients must be afebrile for > 48 hours off antibiotics). Active infections Patients with active infections. The principal investigator (PI) is the final arbiter of the eligibility; Infections such as pneumonia or wound infections that would preclude protocol therapy. Other active infections aside from hepatitis FOR ALL PHASES (Ib AND II): Uncontrolled infection; active, clinically serious infections (> CTCAE grade 2) No active infections Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility Active infections within 48 hours of study entry Evidence of active infections =< 7 days prior to initiation of study drug therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry) Known active infections CELL PROCUREMENT: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-respiratory syncytial virus (RSV), isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excluded LYMPHODEPLETION: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-RSV, isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excluded Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility Active clinically serious infections (> CTCAE grade 2) Active known clinically serious infections Evidence of active infections ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Evidence of active infections Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved Have active, acute, or chronic clinically significant infections. Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and Leishmania infections. Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved Recent or ongoing serious infections within 2 weeks Active serious infections not controlled by antibiotics Evidence of active infections Active serious infections not controlled by antibiotics Known infections: Active clinically serious infections (? CTCAE v4.03 Grade 2). Active infections Active infections or oral temperature > 38.2ยบ Celsius (C) within 48 hours of study entry They have active infections such as hepatitis or fungal infections. Active, unresolved infections required parenteral antimicrobial therapy for active, intercurrent infections Active clinically serious infections (> grade 2) Active clinically serious infections > CTCAE Grade 2 Infections such as pneumonia or wound infections that would preclude protocol therapy Active clinically serious infections Any evidence of serious active infections Patients must not have any active infections Active serious infections not controlled by antibiotics Active hepatitis or other active infections Patients with active clinical infections Active infections not responding to therapy; all efforts should be made to clear the infection prior to enrollment Known active infections c. Active or failed to control serious infections (CTCAE version 4.03 > grade 2 infections) Known active infections Active clinically serious infections (i.e. patients currently taking antibiotics)( Grade 2 NCI-CTC Version 3.0) Any evidence of serious active infections. DONOR: No active or chronic infections 8. Any evidence of serious active infections. Patients with active infections, including HIV, will be excluded Any evidence of serious active infections Infections Active clinically serious infections of > Grade 2 and/or active infections that require treatment with systemic agent Patients with important infections requiring antibiotics are INELIGIBLE, but patients who acquire minor infections while on the study may remain on the study Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility Active clinically serious infections of > Grade 2 Patients with any active hepatitis infections. Patients must have no evidence of active infections at the time of transplantation Patient with active infections Treatment may be given to eligible patients with a single or multiple infections; patients with multiple infections with one or more reactivation and one or more controlled infection are eligible to enroll active infections of the oral cavity Active infection (except mild upper respiratory infections) Patients with clinically significant active infections Patients with known active treatment for hepatitis B and C infections Active serious infections not controlled by antibiotics Patients should not have active infections or concurrent neoplastic disease except for skin cancer Active acute infection (i.e. currently treated with antibiotics); patients with chronic infections such as hepatitis B or C, mycobacterium avium or similar infections will be eligible provided they meet all other eligibility criteria Patients with known active treatment for hepatitis B and C infections Clinically active hepatitis A, B, or C infections Active infections of oral cavity Patients with active treatment for active hepatitis B and C infections Patients with active infections.